Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.74
-0.08 (-1.37%)
Mar 6, 2026, 11:42 AM EST - Market open
Protara Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Protara Therapeutics stock have an average target of 21.86, with a low estimate of 12 and a high estimate of 27. The average target predicts an increase of 280.84% from the current stock price of 5.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protara Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 4 | 4 | 4 |
| Buy | 3 | 2 | 2 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $27 | Buy | Initiates | $27 | +370.38% | Mar 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +300.70% | Feb 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $24 | Buy | Initiates | $24 | +318.12% | Jan 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +300.70% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +300.70% | Nov 19, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.28
from -2.17
EPS Next Year
-1.48
from -1.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.16 | -1.07 | ||||
| Avg | -1.28 | -1.48 | ||||
| Low | -1.33 | -1.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.